elucidating biomarkers of prognosis of 177lu-psma-617-based therapy
Published 2 years ago • 34 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc